Compounded Peptides: The 10 Conditions in HHS's New 503A Policy, and What Evidence Sits Behind Them

If you have been wondering whether compounded peptides are now allowed, the short answer is: partly, under conditions, and not as an approval. This page walks through what the policy actually says, using the document itself.

What is the HHS policy on compounded peptides?

The notice is 91 FR 68526, document 2026-22192. It calls the policy a draft. It says the policy covers the period while the official list of allowed compounding ingredients, the 503A bulks list, is developed through rulemaking.

The policy text, which HHS publishes as a PDF with its appendices, says compounded drugs are not FDA approved. The FDA does not review their safety, effectiveness or quality before they are sold. The same PDF says HHS may revisit the policy if a safety signal or a product quality problem shows up.

For the vote history and the April 2026 list changes, read our tracker, FDA peptide status in 2026. This post goes deeper on one thing the tracker could not cover: the conditions inside the policy.

Which six peptides does the policy name?

The routes below are a record of what Appendix B of the HHS policy describes. They are not advice for any person.

HHS also writes that the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of each peptide on this list. An advisory vote, not a decision, is what that was. The policy leans on those votes as one of its stated reasons.

What are the ten conditions for 503A peptides?

Here is the list, in plain English, from the policy's own wording.

1. 01The peptide must appear in Appendix A.
2. 02It must match the identity and route limits in Appendix B, including sequence, structure and molecular weight.
3. 03It must come from a facility registered with the FDA under section 510 and have a valid certificate of analysis.
4. 04The original maker, not just a reseller, must be registered, follow current good manufacturing practice, and be named on the certificate.
5. 05The pharmacy must report products made, serious adverse events and quality problems to the FDA's MedWatch program and to the states involved.
6. 06The label must say: "This is a compounded drug product. Not for resale."
7. 07Each product may contain only one active ingredient from Appendix A.
8. 08An oral form needs documentation that it reaches an adequate level in the human body.
9. 09The only delivery device packed with the product is an FDA 510(k) cleared syringe.
10. 10The product must follow every other part of the law, including clean conditions and a patient-specific prescription.

Condition 10 matters most for readers. A patient-specific prescription is what 503A compounding is. Nothing in the policy turns a vial labeled for research into a legal product.

Why is the certificate of analysis the center of the policy?

In the policy's words, the limited compounding it allows gives patients "a more controlled alternative" to research-use-only products. That is HHS's stated reason, and you can read it in the policy PDF. Whether it works in practice is a separate question the document does not answer.

The testing standard in Appendix B is long. It lists tests for identity, assay, peptide-related impurities, residual solvents, elemental impurities, bioburden and bacterial endotoxins. It also asks for the certificate to name the method used and the reference standards behind it.

If you want to understand what a good certificate looks like, our guide how to read a peptide certificate of analysis walks through each line. The same ideas apply here.

What does human evidence say about these peptides?

According to a systematic review in Acta Orthopaedica Belgica (October 2026), only three studies in 30 people met its criteria for BPC-157. They were a retrospective study of knee injections (16 people), a retrospective pilot in interstitial cystitis (12 people) and a pilot of intravenous safety (2 people). The authors rated the studies poor in quality and the overall certainty very low.

Those authors also wrote that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality trials. That is their conclusion, and it sits uneasily next to a policy that allows compounding. Both facts are worth holding at once.

An earlier review, published in HSS Journal in 2025, found 36 studies on BPC-157, of which 35 were preclinical and one was clinical.

For Epitalon, a 2026 narrative review in the International Journal of Molecular Sciences says human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa. It also says no adequately powered randomized trial has established therapeutic benefit, and that dose-ranging and long-term safety data remain inadequate.

For MOTS-c, the policy cites a randomized placebo-controlled trial of an analogue. We could verify one early study of an analogue called CB4211: NCT03998514 is a randomized, double-blind, placebo-controlled phase 1 study, sponsored by CohBar, with 88 people enrolled. The registry lists the study as completed. It tests safety and how the body handles the drug. An analogue is a different molecule, so it does not show what MOTS-c itself does.

What do animal studies add?

In mice, a 2008 study in Inflammatory Bowel Diseases found that the tripeptide KPV reduced inflammation in two models of colitis, and that treated mice recovered weight sooner. This was an animal study. It did not test people.

HHS itself leans on mechanism and absence of reported harm for several peptides. For example, its policy describes the FDA staff's safety concerns for TB-500, Epitalon and Semax as "inferential" or "mechanistic" rather than observed. That is HHS's reading. The policy also records that the FDA's drug center (CDER) recommended against listing each of them.

A concern that has not been seen is not the same as a safety record. Neither side of this debate has the large human trials that would settle it.

What does the policy not do?

• It is enforcement discretion, not approval. The FDA has not reviewed these products for safety or effectiveness.
• It does not add the six peptides to the 503A bulks list. That needs rulemaking.
• It covers 503A compounding with a prescription. It is not a rule for online research vials.
• It can change. HHS says it may revisit the policy if a safety signal or quality problem arises.
• It does not tell you what is right for your body. Only a clinician who knows you can do that.

Some readers will see the policy as long-overdue access. Others will see it as moving ahead of the science. The document supports parts of both views, and we try to show each one fairly.

What questions are worth bringing to a clinician or pharmacy?

• Is the product a single active ingredient from the Appendix A list?
• Can the pharmacy show a certificate of analysis that names the original manufacturer?
• Does the label say it is a compounded drug product?
• How are side effects and quality problems reported to the FDA?
• What evidence in people supports this use, and how strong is it?
• Are you being told this is approved? It is not.

These are questions, not a checklist for treatment. Your clinician decides what applies to you. Reported effects by drug class, kept separate from this policy, are in peptide side effects by class.

Baseline lab work can also help a conversation, and our bloodwork plan is free.

When do public comments close on the HHS peptide policy?

Comments go to docket HHS-OASH-2026-0496 on regulations.gov. HHS says public comments may give the FDA additional evidence to consider in rulemaking, so the evidence you can point to is the part that counts.

On November 9, 2026, the date of this page, the regulations.gov API showed the comment period as open. The notice itself calls the policy a draft. A draft can change after comments, and the PDF already says HHS may revisit the policy if a safety signal or a quality problem appears.